What is ARA-290?
ARA-290, also known as cibinetide, is a synthetic 11-amino-acid peptide modelled on part of the helix B region of erythropoietin (EPO). It was designed to act on the innate repair receptor without stimulating red blood cell production, which is EPO’s main effect. It has been developed by Araim Pharmaceuticals and studied in clinical trials of small fibre neuropathy, including in people with sarcoidosis.
ARA-290 product specifications
- Compound: ARA-290 (cibinetide)
- Sequence: pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (11 amino acids; pGlu = pyroglutamic acid)
- Molecular formula: C51H84N16O21
- Molecular weight: about 1257.3 g/mol
- Vial sizes: 10mg and 16mg
Regulatory status
ARA-290 is an investigational compound. It is not an approved medicine in the US, UK, EU or Canada. This product is sold for laboratory research use only.
Related research peptides
- KPV is another short peptide studied in inflammation research.
- B7-33 is another peptide derived from a natural hormone, in this case relaxin-2.
Available sizes: 10mg and 16mg
ARA-290 is offered in two vial sizes: 10mg and 16mg. Both contain the same peptide. The figure is the total amount of peptide in the vial, supplied as a dry (lyophilised) powder; it is not a concentration, so a larger vial is not “stronger”, it simply holds more material. Tell us which size you need when you contact us on Telegram or by email.
Handling and research-use notice
Store and handle this material as stated on the label and certificate of analysis for your batch; see our guide to storing research peptides. This product is sold for laboratory research use only. It is not a medicine or supplement and is not for human or veterinary use.
